CBIO
Crescent Biopharma, Inc.
There isn't enough reported data to score CBIO yet.
CBIO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CBIO's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
CBIO PE Valuation
CBIO has no meaningful PE right now: it lost money over the past year.
CBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect CBIO's losses to shrink, with revenue declining.
CBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$17.88 | +$44.12 |
| Q2 2025 | -$31.37 | +$29.63 |
| Q1 2025 | -$46.00 | +$12.00 |
| Q4 2024 | -$59.00 | -$1.00 |
| Q3 2024 | -$62.00 | +$2.00 |
| Q2 2024 | -$61.00 | +$5.00 |
| Q1 2024 | -$58.00 | +$20.00 |
| Q4 2023 | -$58.00 | +$31.00 |
CBIO is still losing money, but far less than before: $17.88 per share over the past year, against $134.65 at its worst in late 2019.
CBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2022 | $75K | +52717% |
| Q4 2021 | $17.6K | -89% |
| Q3 2021 | $86.6K | -91% |
| Q1 2021 | $1.1M | -88% |
CBIO's revenue is growing: $3M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1280% | N/A |
| Q1 2026 | -2380% | N/A |
| Q2 2022 | -17804% | +10126197 points |
| Q4 2021 | -98870% | -89315 points |
| Q3 2021 | -20029% | -18656 points |
| Q2 2021 | -10144001% | N/A |
| Q1 2021 | -1353% | -1263 points |
| Q4 2020 | -9555% | N/A |
CBIO's operating margin was −1280% last quarter, up 18749 points from the same quarter a year ago.
CBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.9M | -$8.8M |
| Q4 2025 | -$26.9M | -$23.2M |
| Q3 2025 | -$18.1M | -$10.1M |
| Q4 2024 | -$3.7M | +$3.9M |
| Q3 2024 | -$8M | +$696.7K |
| Q2 2024 | -$8.9M | -$1.9M |
| Q1 2024 | -$10.5M | +$1.1M |
| Q4 2023 | -$7.6M | +$295.8K |
CBIO has burned cash in almost every quarter: −$82M over the past year, against −$39M the year before.
CBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.7% | +1.8M shares |
| 1 year | +180% | +25M shares |
| 3 years | +5944% | +38.3M shares |
| 5 years | +7443% | +38.4M shares |
| Available history | +8892% | +38.5M shares |
CBIO has 39M diluted shares, up 180% from a year ago.
CBIO Net Leverage
CBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.5 | Neutral |
| Stochastic | 19.1 | Oversold |
CBIO's weekly RSI is 46 (neutral) and its Stochastic is 19 (oversold).
CBIO PE vs Healthcare Sector
CBIO has no meaningful PE right now: it lost money over the past year.
CBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.7 | 5.2% above |
| 20 week MA | $15.8 | 8.8% below |
| 50 week MA | $15.4 | 6.7% below |
| 100 week MA | $17.3 | 17% below |
| 200 week MA | $80.5 | 82% below |
CBIO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 82% below its 200-week average.
CBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $570.0 | $412.0 | -28% |
| 2021 | $412.0 | $160.0 | -61% |
| 2022 | $160.0 | $227.0 | +42% |
| 2023 | $227.0 | $236.0 | +4% |
| 2024 | $236.0 | $23.6 | -90% |
| 2025 | $23.6 | $12.4 | -48% |
| 2026 YTD | $12.4 | $14.4 | +16% |
CBIO has finished lower in four of the last six years. It's up 16% so far in 2026.